Pharmacotherapy for the treatment of patients with type 2 diabetes mellitus: Rationale and specific agents

被引：30

作者：

Cefalu, W. T. ^{[1
]}

Waldman, S.

Ryder, S.

机构：

[1] Louisiana State Univ, Div Nutr & Chron Dis, Pennington Biomed Res Ctr, Baton Rouge, LA 70803 USA

[2] Thomas Jefferson Univ, Div Clin Pharmacol, Dept Med, Philadelphia, PA 19107 USA

[3] Thomas Jefferson Univ, Div Clin Pharmacol, Dept Biochem, Philadelphia, PA 19107 USA

[4] Thomas Jefferson Univ, Div Clin Pharmacol, Dept Mol Pharmacol, Philadelphia, PA 19107 USA

[5] Pfizer Global R&D, New London, CT USA

来源：

CLINICAL PHARMACOLOGY & THERAPEUTICS | 2007年 / 81卷 / 05期

关键词：

D O I：

10.1038/sj.clpt.6100156

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Type 2 diabetes, the most common form of diabetes, is characterized by abnormalities in hepatic glucose production, insulin resistance, and a progressive decline in beta-cell function over time. To treat effectively the individual with type 2 diabetes, the provider must have a thorough understanding of the underlying pathophysiology to provide treatment that precisely addresses the metabolic abnormalities. Currently, the provider who cares for subjects with type 2 diabetes can choose an antidiabetic agent from no less than eight pharmacologic classes. These classes include agents that increase insulin secretion, improve insulin action, and delay absorption of carbohydrates. The newer treatments available, specifically incretin therapy, address a previously unmet need in diabetes by modulating glucose supply. The currently available agents can be combined and combination therapy markedly improves glycemic control. This allows the provider to design regimens to specifically address underlying abnormalities. A review of all currently available agents is provided.

引用

页码：636 / 649

页数：14

共 81 条

[11] Effects of pioglitazone and rosiglitazone on blood lipid levels and glycemic control in patients with type 2 diabetes mellitus: A retrospective review of randomly selected medical records [J].

Boyle, PJ ;

King, AB ;

Olansky, L ;

Marchetti, A ;

Lau, H ;

Magar, R ;

Martin, J .

CLINICAL THERAPEUTICS, 2002, 24 (03) :378-396

[12] Point: Pulmonary inhalation of insulin: Another "brick in the wall"" [J].

Cefalu, William T. .

DIABETES CARE, 2007, 30 (02) :439-441

[13] Evolving strategies for insulin delivery and therapy [J].

Cefalu, WT .

DRUGS, 2004, 64 (11) :1149-1161

[14]

Cefalu WT, 1998, DRUG DEVELOP RES, V44, P1

[15] Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone [J].

Charbonnel, Bernard ;

Karasik, Avraham ;

Liu, Ji ;

Wu, Mei ;

Meininger, Gary .

DIABETES CARE, 2006, 29 (12) :2638-2643

[16] Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance - The STOP-NIDDM Ttrial [J].

Chiasson, JL ;

Josse, RG ;

Gomis, R ;

Hanefeld, M ;

Karasik, A ;

Laakso, M .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2003, 290 (04) :486-494

[17] Prevalence of diabetes and impaired fasting glucose in adults in the US population - National Health and Nutrition Examination Survey 1999-2002 [J].

Cowie, Catherine C. ;

Engelgau, Michael M. ;

Rust, Keith F. ;

Saydah, Sharon H. ;

Byrd-Holt, Danita D. ;

Williams, Desmond E. ;

Eberhardt, Mark S. ;

Geiss, Linda S. ;

Flegal, Katherine M. ;

Gregg, Edward W. .

DIABETES CARE, 2006, 29 (06) :1263-1268

[18]

Davies Melanie J, 2002, Curr Med Res Opin, V18 Suppl 1, ps22, DOI 10.1185/030079902125000200

[19] Pharmacologic therapy for type 2 diabetes mellitus [J].

DeFronzo, RA .

ANNALS OF INTERNAL MEDICINE, 1999, 131 (04) :281-303

[20] EFFICACY OF METFORMIN IN PATIENTS WITH NON-INSULIN-DEPENDENT DIABETES-MELLITUS [J].

DEFRONZO, RA ;

GOODMAN, AM ;

ABELOVE, W ;

REID, E ;

PITA, J ;

CALLAHAN, M ;

JOHNSON, D ;

PELAYO, E ;

PUGH, J ;

SHANK, M ;

GARZA, P ;

HAAG, B ;

KORFF, J ;

ANGELO, A ;

IZENSTEIN, B ;

VANDERLEEDEN, M ;

CATHCART, H ;

TIERNEY, M ;

BIGGS, D ;

KARAM, J ;

NOLTE, M ;

GAVIN, L ;

ELDER, MA ;

CORBOY, J ;

THWAITE, D ;

WONG, S ;

DAVIDSON, M ;

PETERS, A ;

DUNCAN, T ;

KERCHER, S ;

FISCHER, J ;

KIPNES, M ;

RADNICK, BJ ;

ROURA, M ;

ROQUE, J ;

MONTGOMERY, C ;

COLLUM, P ;

RUST, M ;

POHL, S ;

PFEIFER, M ;

ALLWEISS, P ;

LEICHTER, S ;

LEACH, P ;

GALLINA, D ;

MUSEY, V ;

BERKOWITZ, K ;

EASTMAN, R ;

TAYLOR, T ;

DELAPENA, MS ;

ZAWADSKI, J .

NEW ENGLAND JOURNAL OF MEDICINE, 1995, 333 (09) :541-549

← 1 2 3 4 5 6 7 8 9 →